Cas:25104-37-4 poly(vinyl ethyl ether) manufacturer & supplier

We serve Chemical Name:poly(vinyl ethyl ether) CAS:25104-37-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

poly(vinyl ethyl ether)

Chemical Name:poly(vinyl ethyl ether)
CAS.NO:25104-37-4
Synonyms:MFCD00084462
Molecular Formula:C4H8O
Molecular Weight:72.10570
HS Code:

Physical and Chemical Properties:
Melting point:-115ºC
Boiling point:35ºC
Density:0.751 g/cm3
Index of Refraction:n20/D 1.454(lit.)
PSA:9.23000
Exact Mass:72.05750
LogP:1.16640

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like MFCD00084462 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00084462 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00084462 Use and application,MFCD00084462 technical grade,usp/ep/jp grade.


Related News: Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. poly(vinyl ethyl ether) manufacturer With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs. poly(vinyl ethyl ether) supplier With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs. poly(vinyl ethyl ether) vendor Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. poly(vinyl ethyl ether) factory ��Inceptua Medicines Access is delighted to be selected as Onconova��s partner for the Pre-approval Access Program for rigosertib.